Certificate PL-26-00137 · ARA-290 10 mg Nasal Spray · lot PL-2610-015 · branded for Epic Wholesalers LLC -dba-Epic Peptides Lab
VerifyCertificate page
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · Lot release
www.epicpeptideslab.com
Certificate no.
PL-26-00137
Verification key
JCFMVYFX
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab

ARA-290 10 mg Nasal Spray

Lot PL-2610-015 · Solution · Label claim 10 mg per bottle
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-015
Date made
2026-10-01
Date of analysis
2026-10-02
Date issued
2026-10-08
Retest / expiry
2028-10-01
Units in lot / sampled
366 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
ARA-290
Cibinetide; erythropoietin helix-B surface peptide
CAS number
1208243-50-8
Molecular formula
C51H84N16O21
Theoretical mass (avg.)
1,257.30 Da
Sequence
ZEQLERALNSS
Purity · RP-HPLC, area %
99.55%
Specification ≥ 99.0% • main peak at 11.25 min
Identity · Observed Mass
1,257.26 Da
Theoretical 1,257.30 Da • −0.04 Da (32 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da1,257.26 DaPASS
PurityRP-HPLC, UV 214 nm, area%≥ 99.0%99.55%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.19% (RT 10.10)PASS
Assay (label claim)Assay vs label claim9.5–10.5 mg/bottle9.91 mg/bottlePASS
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.276 EU/mgPASS
Aerobic count (TAMC)USP <61>< 10 CFU/mL< 10 CFU/mLPASS
Yeast & mold (TYMC)USP <61>< 10 CFU/mL< 10 CFU/mLPASS
E. coliUSP <62>AbsentAbsentPASS

1HPLC chromatogram

Data file: PL-2610-015-HPLC.raw · Column C18, 150 × 4.6 mm · UV 214 nm
0.01%0.1%1%10%100%91011121314Retention time (min) · stick height = area % (log scale)99.55% · 11.25 min0.19% †0.13% †0.13% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-015-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · continued
ARA-290 10 mg Nasal Spray · Lot PL-2610-015 · Certificate PL-26-00137
Lot PL-2610-015
Method, peak table and approval

2HPLC method · PL-2610-015-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
110.10 †—0.19
211.25—99.55
311.90 †—0.13
412.80 †—0.13
Total—100.00
Peaks: 1 deamidation product; 2 main peak (ARA-290); 3 truncated sequence; 4 unidentified impurity · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (charge)
629.66 (2+) · 420.11 (3+)
Deconvoluted Mass
1,257.26 Da
Theoretical Mass
1,257.30 Da
Difference
−0.04 Da (32 ppm)
Data File
PL-2610-015-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Assay vs label claimPrymaLab Analytical2026-10-02—
Endotoxin (LAL, kinetic)PrymaLab Analytical2026-10-02—
Microbial limits (USP <61>/<62>)PrymaLab Analytical2026-10-08—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-08
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-08
M. Phelps
Lab Director · approved for release
Date: 2026-10-08